FAQ on Tonix Pharmaceuticals' TNX-1700 Preclinical Data Presentation at AACR 2025
Summary
Tonix Pharmaceuticals presented promising preclinical data for TNX-1700, its immuno-oncology candidate, at AACR 2025, showing potential in enhancing anti-tumor immune responses in gastric cancer models, especially when combined with anti-PD1 therapy.
What is TNX-1700 and what does it target?
TNX-1700 is Tonix Pharmaceuticals’ lead immuno-oncology candidate, a fusion protein version of TFF2, designed to target the tumor microenvironment in gastric and colon cancers by reducing immunosuppressive neutrophils and enhancing anti-tumor immune responses.
Why is the presentation of TNX-1700’s preclinical data at AACR 2025 significant?
The presentation is significant because it showcases positive preclinical results indicating TNX-1700’s potential to improve treatment outcomes for gastric cancer, especially in combination with anti-PD1 therapy, marking a step forward in immuno-oncology research.
How does TNX-1700 work in gastric cancer models?
In gastric cancer models, TNX-1700 works by significantly reducing immunosuppressive neutrophils and enhancing the body’s anti-tumor immune responses, particularly when used alongside anti-PD1 therapy.
Who is developing TNX-1700 and under what agreement?
Tonix Pharmaceuticals is developing TNX-1700 under a license from Columbia University, as part of its strategy to innovate treatments targeting the tumor microenvironment in cancers like gastric and colon.
Where can I find more information about Tonix Pharmaceuticals and TNX-1700?
More information about Tonix Pharmaceuticals and TNX-1700 can be found on the company’s website at www.TonixPharma.com and in the full press release at https://ibn.fm/SseO1.
What other products or candidates does Tonix Pharmaceuticals have in development?
Tonix Pharmaceuticals has a diverse development portfolio including CNS disorders, immunology, rare diseases, and infectious diseases, with notable candidates like TNX-102 SL for fibromyalgia, TNX-1300 for cocaine intoxication, and TNX-1500 for preventing allograft rejection and treating autoimmune diseases.
Has TNX-102 SL received any FDA designations?
Yes, TNX-102 SL has been granted Fast Track designation by the FDA for the management of fibromyalgia, following two statistically significant phase 3 studies.
What is the significance of the DoD contract awarded to Tonix Pharmaceuticals?
The U.S. Department of Defense awarded Tonix a contract up to $34 million over five years to develop TNX-4200, small molecule broad-spectrum antiviral agents, highlighting the company’s role in addressing biological threats and improving military medical readiness.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 118783